^
    1m
    Phase II Study Evaluating the Combination of Linperlisib, Azacitidine, and Liposomal Mitoxantrone in Treatment-Naïve Nodal TFH Cell Lymphoma (ChiCTR2500107944)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Zepsun (donafenib) • Itari (linperlisib) • Duoenda (mitoxantrone liposomal)
    2ms
    Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    Tazverik (tazemetostat) • Itari (linperlisib) • golidocitinib (DZD4205)
    3ms
    Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • Itari (linperlisib)
    4ms
    A Prospective, Single-Arm, Single-Center Study on the Safety and Efficacy of Linperlisib (a PI3Kδ Inhibitor) Combined with Azacitidine in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (R/R PTCL) (ChiCTR2500104258)
    P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    azacitidine • Itari (linperlisib)
    4ms
    Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=41, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Itari (linperlisib)
    5ms
    Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial. (PubMed, JAMA Dermatol)
    This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides. ClinicalTrials.gov Identifier: NCT06037239.
    Clinical • Journal
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    Epidaza (chidamide) • Itari (linperlisib)
    6ms
    Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a Case Report. (PubMed, Front Pharmacol)
    We present the case of an 80-year-old woman with relapsed/refractory (R/R) AITL who relapsed after CHOP and exhibited resistance to the following sequential therapies: second-line chidamide plus COP and third-line chidamide with mitoxantrone hydrochloride liposome...Salvage therapy with linperlisib, a selective PI3Kδ inhibitor, combined with gemcitabine/oxaliplatin induced sustained partial remission, followed by linperlisib maintenance...This case highlights the dual role of linperlisib as an effective and well-tolerated therapy for elderly R/R AITL patients who have exhausted prior lines. By precisely targeting PI3Kδ, our findings offer critical real-world evidence to address the unmet need for safe salvage strategies in this vulnerable population.
    Journal
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    IDH2 mutation
    |
    gemcitabine • oxaliplatin • Epidaza (chidamide) • Itari (linperlisib) • Duoenda (mitoxantrone liposomal)
    8ms
    KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia. (PubMed, Cell Rep Med)
    In a pilot trial of linperlisib (a PI3Kδ inhibitor) for refractory cases, 7 of 8 participants quickly respond with satisfactory safety. This study is registered at ClinicalTrials.gov (NCT05676710).
    Journal
    |
    CD8 (cluster of differentiation 8) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • KLRG1 (Killer Cell Lectin Like Receptor G1)
    |
    Itari (linperlisib)
    9ms
    Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • Itari (linperlisib)
    10ms
    Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Epidaza (chidamide) • Itari (linperlisib)
    10ms
    PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial. (PubMed, Cancer Cell Int)
    This study highlights the potential of linperlisib plus GEMOX as a treatment for R/R DLBCL, demonstrating a tolerable safety profile and encouraging efficacy results.
    P1/2 data • Journal
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    gemcitabine • oxaliplatin • Itari (linperlisib)
    10ms
    Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Sun Yat-sen University
    New P1 trial
    |
    Tyvyt (sintilimab) • Itari (linperlisib)